Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
LONDON - MedPal AI Plc (AIM:MPAL) announced Wednesday it is conducting a retail offer to raise up to £1 million through the issuance of up to 12.5 million new ordinary shares at 8 pence per share.
The digital health platform said the proceeds will fund its strategy following its acquisition of assets from Universal Pharmacy Ltd (in administration), which will enable the company to establish itself in the GLP-1 agonist market for obesity treatment, including drugs such as semaglutide.
The share price represents a 5.9 percent discount to the mid-market closing price on September 30, 2025, according to the company’s statement.
MedPal AI is making the offer through the Winterflood Retail Access Platform (WRAP) to eligible investors in the United Kingdom, with a minimum subscription amount of £100 per investor. The offer is expected to close at 9:00 p.m. on October 1, 2025.
The company noted that the retail offer is separate from a placing announced separately and is conditional on the new shares being admitted to trading on AIM, which is anticipated to occur on October 8, 2025.
Retail investors interested in subscribing should contact their broker or wealth manager to confirm participation in the offer. The company reserves the right to amend the size of the offer and to scale back orders at its discretion.
The announcement stated that the retail offer is being made under exemptions from the requirement to publish a prospectus under UK financial regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.